Disruption of redox homeostasis for combinatorial drug efficacy in K-Ras tumors as revealed by metabolic connectivity profiling

Autor: Daniela Gaglio 1, 2, Marcella Bonanomi 2, 3, Silvia Valtorta 1, 4, Rohit Bharat 23, Marilena Ripamonti 1, Federica Conte 2, 5, Giulia Fiscon 2, Nicole Righi 2, Elisabetta Napodano 1, Federico Papa 2, Isabella Raccagni 1, 6, Seth J Parker 7, 8, Ingrid Cifola 9, Tania Camboni 9, Paola Paci 2, Anna Maria Colangelo 2, Marco Vanoni 2, Christian M Metallo 7, Rosa Maria Moresco 1, Lilia Alberghina 2

Publikováno v: Cancer & Metabolism, Vol 8, Iss 1, Pp 1-15 (2020)
Cancer & metabolism 8 (2020): 22. doi:10.1186/s40170-020-00227-4
info:cnr-pdr/source/autori:Daniela Gaglio 1,2, Marcella Bonanomi 2,3, Silvia Valtorta 1,2,4, Rohit Bharat 23, Marilena Ripamonti 1,2, Federica Conte 2,5, Giulia Fiscon 2,5, Nicole Righi 2,3, Elisabetta Napodano 1,2, Federico Papa 2,5, Isabella Raccagni 1,2,6, Seth J Parker 7,8, Ingrid Cifola 9, Tania Camboni 9, Paola Paci 2,5,10, Anna Maria Colangelo 2,3, Marco Vanoni 2,3, Christian M Metallo 7,8, Rosa Maria Moresco 1,2,4, Lilia Alberghina 2,3/titolo:Disruption of redox homeostasis for combinatorial drug efficacy in K-Ras tumors as revealed by metabolic connectivity profiling/doi:10.1186%2Fs40170-020-00227-4/rivista:Cancer & metabolism/anno:2020/pagina_da:22/pagina_a:/intervallo_pagine:22/volume:8
Cancer & Metabolism

Abstract Background Rewiring of metabolism induced by oncogenic K-Ras in cancer cells involves both glucose and glutamine utilization sustaining enhanced, unrestricted growth. The development of effective anti-cancer treatments targeting metabolism m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950f4c1a96c7b0580200136e0d3aea0e
http://link.springer.com/article/10.1186/s40170-020-00227-4

Metabolic Evaluation of Non–Small Cell Lung Cancer Patient–Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response

Autor: Silvia Valtorta* 1, 2, Massimo Moro* 3, Giovanna Prisinzano 1, 4, Giulia Bertolini 3, Monica Tortoreto 5, Isabella Raccagni 2, Ugo Pastorino 6, Luca Roz 3, Gabriella Sozzi +3, Rosa Maria Moresco +2, 4 *Contributed equally to this work. +Contributed equally to this work.

Publikováno v: The Journal of nuclear medicine (1978) 58 (2017): 42–47. doi:10.2967/jnumed.116.176404
info:cnr-pdr/source/autori:Silvia Valtorta* 1,2, Massimo Moro* 3, Giovanna Prisinzano 1,4, Giulia Bertolini 3, Monica Tortoreto 5, Isabella Raccagni 2,4, Ugo Pastorino 6, Luca Roz 3, Gabriella Sozzi +3 and Rosa Maria Moresco +2,4 *Contributed equally to this work. +Contributed equally to this work./titolo:Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response./doi:10.2967%2Fjnumed.116.176404/rivista:The Journal of nuclear medicine (1978)/anno:2017/pagina_da:42/pagina_a:47/intervallo_pagine:42–47/volume:58
The Journal of nuclear medicine (1978. Online) (2016). doi:10.2967/jnumed.116.176404
info:cnr-pdr/source/autori:Silvia Valtorta, Massimo Moro, Giovanna Prisinzano, Giulia Bertolini, Monica Tortoreto, Isabella Raccagni, Ugo Pastorino, Luca Roz, Gabriella Sozzi, and Rosa Maria Moresco/titolo:Metabolic evaluation of non-small cell lung cancer patient-derived xenografts models using [18F]FDG PET: potential tools for early therapy response/doi:10.2967%2Fjnumed.116.176404/rivista:The Journal of nuclear medicine (1978. Online)/anno:2016/pagina_da:/pagina_a:/intervallo_pagine:/volume

PURPOSE: Lung cancer heterogeneity makes response to therapy extremely hard to predict. Patient-derived xenografts (PDXs) represent a reliable preclinical model that closely recapitulates the main characteristics of the primary tumor and could repres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10070ebc3b8ac5b4544bfee6a7ebc525
https://doi.org/10.2967/jnumed.116.176404

Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

Autor: Silvia Valtorta 1, 2, 3, 4, Alessia Lo Dico 5, Isabella Raccagni 1, Daniela Gaglio 2, Sara Belloli 2, Letterio S. Politi 6, 7, 8, Cristina Martelli 5, Cecilia Diceglie 5, 1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5, 9, Luisa Ottobrini 2, 5, Rosa Maria Moresco 1

Publikováno v: Oncotarget (2017).
info:cnr-pdr/source/autori:Silvia Valtorta 1,2,3,4,*, Alessia Lo Dico 5,*, Isabella Raccagni 1,2,3,4, Daniela Gaglio 2,4, Sara Belloli 2,3,4, Letterio S. Politi 6,7,8, Cristina Martelli 5, Cecilia Diceglie 5,1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5,9, Luisa Ottobrini 2,5,* and Rosa Maria Moresco 1,2,3,4,*/titolo:Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models/doi:/rivista:Oncotarget/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) is the standard therapy, but response is heterogeneous and life expectancy is limited.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::7ffbe54f58bfb27b307ca2d8e493dcce
https://publications.cnr.it/doc/379984